SEC Filing Analysis: NEOGEN CORP (NEOG)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director of NEOGEN CORP was awarded Restricted Stock Units (RSUs) and stock options as part of a standard compensation package. The transaction's value is immaterial relative to the company's market capitalization.
• Market Impact: This filing is unlikely to have any significant impact on the stock price, as it represents routine director compensation rather than an open-market transaction reflecting insider sentiment.

Company Information

Field	Value
Company	NEOGEN CORP
Ticker Symbol	NEOG
CIK	0000711377
Industry	In Vitro & In Vivo Diagnostic Substances
Market Cap	$1.35 billion

Insider Information

Field	Value
Name	Pelossof Avi
CIK	0001293460
Title/Position	null
Relationship	Director

Transaction Details

This filing reported two grants: one for common stock (RSUs) and one for derivative securities (options).

Non-Derivative (RSU Grant)

Field	Value
Form Type	4
Transaction Date	2025-10-24
Transaction Code	A (Award)
Security Type	Common Stock
Shares Involved	19,386
Price Per Share	$6.19
Total Value	$120,000.34
Shares Owned After	19,386
Ownership Type	Direct

Derivative (Option Grant)

Field	Value
Security Type	Common Stock (Right to Buy)
Shares Involved	49,929
Exercise Price	$6.19
Expiration Date	2035-10-24

Financial Impact Assessment

Transaction Materiality (Based on RSU Grant)

Metric	Value
Transaction Value	$120,000.34
% of Market Cap	0.009%
Shares Transacted	19,386
% of Shares Outstanding	0.009%
Post-Transaction Ownership	19,386 shares (0.009% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a company with a market capitalization of $1.35 billion, a transaction valued at approximately $120,000 is financially immaterial. It falls far below the 0.1% threshold for even low significance.
• Ownership Concentration: This grant establishes the director's initial direct holding in the company, which remains very small at less than 0.01% of total shares outstanding.
• Dilution Impact: The combined grants of 19,386 RSUs and 49,929 options represent a potential future issuance of 69,315 shares. This would cause a potential dilution of approximately 0.032% of shares outstanding, which is negligible for existing shareholders.
• Transaction Significance: The transaction is an award (Code 'A'), not an open-market purchase. Such grants are standard practice for director compensation and do not signal new insider sentiment about the company's future prospects.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Equity grants to directors are routine and expected by the market. The size of this grant is too small to influence investor perception or stock price.

Volume & Sentiment

• Expected Volume Impact: Minimal to none. This is not an open-market trade and will not affect trading volume.
• Sentiment Indicator: Neutral. The filing confirms standard corporate governance practices but offers no new bullish or bearish signals.

Investment Insights

Positive Market Indicators

• Aligning director interests with shareholders through equity compensation is a standard positive governance practice.

Risk Factors

• While this specific grant is minor, investors should monitor the aggregate rate of equity compensation to assess long-term dilution risk.

Key Takeaways

1. A NEOGEN director received a standard equity compensation package.
2. The total value of the grants is less than 0.01% of the company's market cap, making it a low-significance event.
3. The potential shareholder dilution from these grants is minimal at ~0.032%.

Additional Context

Transaction Notes

• Vesting Schedule: According to Footnote 1, both the RSUs and the stock options vest in equal annual installments over three years, beginning on the first anniversary of the grant date. This incentivizes long-term alignment with the company's performance.